Tapentadol extended-release for treatment of chronic pain: a review

References

• WadeWESpruillWJTapentadol hydrochloride: a centrally acting oral analgesicClin Ther200931122804281820110020
   PubMed Web of Science ®Google Scholar
• EtropolskiMSOkamotoAShapiroDYRauschkolbCDose conversion between tapentadol immediate and extended release for low back painPain Physician2010131617020119464
   PubMed Web of Science ®Google Scholar
• KleinertRLangeCSteupABlackPGoldbergJDesjardinsPSingle dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled studyAnesth Analg200810762048205519020157
   PubMed Web of Science ®Google Scholar
• AfilaloMEtropolskiMSKuperwasserBEfficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III studyClin Drug Investig2010308489505
   PubMed Web of Science ®Google Scholar
• StegmannJUWeberHSteupAOkamotoAUpmalisDDanielsSThe efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgeryCurr Med Res Opin200824113185319618851776
   PubMed Web of Science ®Google Scholar
• DanielsSEUpmalisDOkamotoALangeCHäeusslerJA randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) painCurr Med Res Opin200925376577619203298
   PubMed Web of Science ®Google Scholar
• HartrickCVan HoveIStegmannJOhCUpmalisDEfficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled studyClin Ther200931226027119302899
   PubMed Web of Science ®Google Scholar
• HaleMUpmalisDOkamotoALangeCRauschkolbCTolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind studyCurr Med Res Opin20092551095110419301989
   PubMed Web of Science ®Google Scholar
• TzschentkeTMJahnelUKogelBTapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single moleculeDrugs Today (Barc)200945748349619834626
   PubMed Web of Science ®Google Scholar
• TerlindenRKogelBYEnglbergerWTzschentkeTMIn vitro and in vivo characterization of tapentadol metabolitesMethods Find Exp Clin Pharmacol2010321313820383344
   PubMedGoogle Scholar
• LangeBKuperwasserBOkamotoAEfficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painAdv Ther201027638139920556560
   PubMed Web of Science ®Google Scholar
• GuayDRIs tapentadol an advance on tramadol?Consult Pharm2009241183384020092221
   PubMedGoogle Scholar
• BuynakRShapiroDYOkamotoAEfficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III studyExpert Opin Pharmacother201011111787180420578811
   PubMed Web of Science ®Google Scholar
• MaxMBLynchSAMuirJShoafSESmollerBDubnerREffects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathyN Engl J Med199232619125012561560801
   PubMed Web of Science ®Google Scholar
• BrileyMClinical experience with dual action antidepressants in different chronic pain syndromesHum Psychopharmacol200419Suppl 1S21S2515378667
   PubMed Web of Science ®Google Scholar
• SloanPTapentadol for acute and chronic painExpert Opin Pharmacother201011111783178520629605
   PubMed Web of Science ®Google Scholar
• PrommerEETapentadol: an initial analysisJ Opioid Manag20106322322620642251
   PubMedGoogle Scholar
• EpsteinDHPrestonKLJasinskiDRAbuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadolBiol Psychol2006731909916497429
   PubMed Web of Science ®Google Scholar
• GrondSSablotzkiAClinical pharmacology of tramadolClin Pharmacokinet2004431387992315509185
   PubMed Web of Science ®Google Scholar
• RadbruchLGrondSLehmannKAA risk-benefit assessment of tramadol in the management of painDrug Saf19961518298862961
   PubMed Web of Science ®Google Scholar
• GillenCHaurandMKobeltDJWnendtSAffinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptorNaunyn Schmiedebergs Arch Pharmacol2000362211612110961373
   PubMed Web of Science ®Google Scholar
• TzschentkeTChristophTKögelB(−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther2007323126527617656655
   PubMed Web of Science ®Google Scholar
• NagarSRaffaRBLooking beyond the administered drug: metabolites of opioid analgesicsJ Fam Pract200857Suppl 6S25S3218655760
   PubMedGoogle Scholar
• HartrickCVan HoveIStegmannJUOhCUpmalisDEfficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled studyClin Ther200931226027119302899
   PubMed Web of Science ®Google Scholar
• TerlindenROssigJFliegertFLangeCGöhlerKAbsorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjectsEur J Drug Metab Pharmacokinet200732316316918062408
   PubMed Web of Science ®Google Scholar
• KneipCTerlindenRBeierHChenGInvestigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytesDrug Metab Lett200821677519356073
   PubMedGoogle Scholar
• SchmidtCOSchweikertBWenigCMModelling the prevalence and cost of back pain with neuropathic components in the general populationEur J Pain200913101030103519201230
   PubMed Web of Science ®Google Scholar
• McDonaldAAPortenoyRKHow to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer painJ Support Oncol200641435216444852
   PubMedGoogle Scholar
• FreynhagenRBaronRGockelUTölleTRpainDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurr Med Res Opin200622101911192017022849
   PubMed Web of Science ®Google Scholar
• DworkinRHO’ConnorABBackonjaMPharmacologic management of neuropathic pain: evidence-based recommendationsPain2007132323725117920770
   PubMed Web of Science ®Google Scholar
• TzschentkeTMChristophTKögelB(−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther2007323126527617656655
   PubMed Web of Science ®Google Scholar
• MonoryKGreinerESartaniaNOpioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinansLife Sci199964222011202010374926
   PubMed Web of Science ®Google Scholar
• MaizelsMMcCarbergBAntidepressants and antiepileptic drugs for chronic non-cancer painAm Fam Physician200571348349015712623
   PubMed Web of Science ®Google Scholar
• AdamsEHChwieckoPAce-WagonerYA study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions – the ACCPT StudyPain Pract20066425426417129306
   PubMedGoogle Scholar
• AvouacJGossecLDougadosMEfficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trialsOsteoarthritis Cartilage200715895796517398122
   PubMed Web of Science ®Google Scholar
• BenyaminRTrescotAMDattaSOpioid complications and side effectsPain Physician200811Suppl 2S105S12018443635
   PubMed Web of Science ®Google Scholar
• GimbelJSRichardsPPortenoyRKControlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trialNeurology200360692793412654955
   PubMed Web of Science ®Google Scholar
• KalsoEEdwardsJEMooreRAMcQuayHJOpioids in chronic non-cancer pain: systematic review of efficacy and safetyPain2004112337238015561393
   PubMed Web of Science ®Google Scholar
• KivitzAMaCAhdiehHGalerBSA 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or kneeClin Ther200628335236416750450
   PubMed Web of Science ®Google Scholar
• SchwartzSEtropolskiMShapiroDYSafety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trialCurr Med Res Opin201127115116221162697
   PubMed Web of Science ®Google Scholar
• ArgoffCEColeBEFishbainDAIrvingGADiabetic peripheral neuropathic pain: clinical and quality-of-life issuesMayo Clin Proc200681Suppl 4S3S1116608048
   PubMed Web of Science ®Google Scholar
• EisenbergEMcNicolEDCarrDBEfficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trialsJAMA2005293243043305215972567
   PubMed Web of Science ®Google Scholar
• FinnerupNBOttoMMcQuayHJJensenTSSindrupSHAlgorithm for neuropathic pain treatment: an evidence based proposalPain2005118328930516213659
   PubMed Web of Science ®Google Scholar
• HaratiYGoochCSwensonMDouble-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathyNeurology1998506184218469633738
   PubMed Web of Science ®Google Scholar
• WatsonCPBabulNEfficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgiaNeurology1998506183718419633737
   PubMed Web of Science ®Google Scholar
• WatsonCPMoulinDWatt-WatsonJGordonAEisenhofferJControlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathyPain20031051–2717814499422
   PubMed Web of Science ®Google Scholar
• AttalNCruccuGHaanpääMEFNS guidelines on pharmacological treatment of neuropathic painEur J Neurol200613111153116917038030
   PubMed Web of Science ®Google Scholar
• PappagalloMIncidence, prevalence, and management of opioid bowel dysfunctionAm J Surg2001182Suppl 5A11S18S11755892
   PubMed Web of Science ®Google Scholar
• WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract201010541642720602712
   PubMed Web of Science ®Google Scholar
• VevesABackonjaMMalikRAPainful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment optionsPain Med20089666067418828198
   PubMed Web of Science ®Google Scholar
• MartinTJEisenachJCPharmacology of opioid and nonopioid analgesics in chronic pain statesJ Pharmacol Exp Ther2001299381181711714863
   PubMed Web of Science ®Google Scholar
• OssipovMHMalseedRTGoldsteinFJAugmentation of central and peripheral morphine analgesia by desipramineArch Int Pharmacodyn Ther198225922222297181579
   PubMedGoogle Scholar
• MillanMJDescending control of painProg Neurobiol200266635547412034378
   PubMed Web of Science ®Google Scholar